Thank you for joining the weekly webinar! We are admitting audience members from the waiting room. Please allow a few moments for the webinar to begin.
HEALEY ALS Platform Trial

Weekly Q&A – February 1, 2024
This trial is dedicated to all people living with ALS, their families, and friends. Your partnership in research is what keeps us filled with passion, dedication, and the commitment to develop new treatments for ALS.

This breakthrough trial would not be possible without your participation.

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality.

Thank You
Common protocol and shared infrastructure allow for operational and scientific efficiencies.

Regimen: Active Study Drug + Matching Placebo

- Common Protocol
- Shared Infrastructure
- Operational and Scientific Efficiencies
- 1 Protocol (Phase 2/3)
- 1 single IRB
- Central Governance
- 7 Regimens
- 70+ Enrolling Sites
- ~1300 Participants
The objective of each regimen is to provide a go / no go decision to inform the clinical development program of the regimen study drug.

**Primary Endpoint (Placebo-Controlled Period)**
Change from baseline through week 24 in disease severity as measured by the ALSFRS-R total score and survival.

**Safety, Secondary, and Exploratory Endpoints**
(respiratory function, muscle strength, survival, biomarkers + regimen-specific endpoints)
Providing research access across a diverse network of 70+ NEALS sites

Contact a study team near you to discuss enrollment opportunities

https://bit.ly/3g2NZr5
Enrollment Update: Regimen F and Regimen G

- 565 participants consented to Master Protocol since RGF and RGG initiated
- 477 participants assigned to RGF or RGG
- 427 participants randomized within RGF or RGG

Thank You for your partnership in ALS research

(as of 2/1/24)
Monthly Expanded Access Q&A Webinars

February 8, 2024 –
EAP Update with Dr. Rick Bedlack (Duke) and Gwen Petersen

January 11, 2024 –
EAP Discussion with the NIH

December 14, 2023 –
EAP Update with Dr. James Berry (MGH)
Recording: https://bit.ly/3UfCAJU

November 9, 2023 –
EAP Update with Dr. Suma Babu (MGH)

February 8, 2024 –
Thurs 5:00-5:30 EST
EAP Update with Dr. Rick Bedlack (Duke) and Gwen Petersen

March 14, 2024 –
Thurs 5:00-5:30 EST
EAP Update with Dr. Jinsy Andrews (Columbia)
Expanded Access Resources and Webinar Opportunities

Join us for updates about Expanded Access and EAPs on the second Thursday of each month!
(or view recordings online)

Visit the NEALS website to explore upcoming educational webinar opportunities or view previous recordings

Find more webinar opportunities and recordings through the International Alliance of ALS/MND Associations

https://bit.ly/3r6Nd2L
https://bit.ly/3S4P0Sb
https://bit.ly/3Obj2m6
The ALS Association/Northeast ALS Consortium Educational Webinar

ALS Treatments: Riluzole, Radicava, and Relyvrio

Register Here:

Monday, March 18th
4:30pm EST

Moderator: Senda Ajroud-Driss, M.D., Northwestern University


Recording will later be available under “educational webinars” on neals.org
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail:healeyalsplatform@mgh.harvard.edu

Weekly webinar registration: https://bit.ly/3r6Nd2L
ALS Link sign-up: https://bit.ly/3o2Ds3m

Upcoming Webinars:
February 8th- EAP Discussion with Dr. Rick Bedlack (Duke) and Gwen Petersen
February 15th- Weekly Q&A and Platform Trial Update
February 22nd- Genetics Discussion with Dr. Mark Garret (MGH)